The Chinese commercial space sector is the hottest front in 21st-century geoeconomic, strategic, and military intelligence competition , currently defined by power asymmetry  and the overwhelming operational dominance of the United States . Beijing's goal of becoming an " aerospace power " is hampered by a "mixed and urgent situation" where the US, via the operational monopoly of SpaceX , has already saturated critical space resources, particularly Low Earth Orbit (LEO) and s

Both China and Russia are significantly strengthening their respective cybersecurity regulatory frameworks. A comparative analysis of the amendments to China's Cybersecurity Law (CSL) (effective January 2026) and the new Russian FSB ordinances ( draft regulatory proposals currently under public consultation , slated to take effect in January 2026) reveals strong analogies  in their strategies for cyberspace control. These reflect common geopolitical trends oriented toward c

The evolution of the Chinese biomedical sector has emerged as the primary critical issue in commercial intelligence and global geoeconomic strategy dynamics. China is no longer merely a leader in generic API production (with an estimated control of 80% of the global supply chain  in 2023), but has completed a strategic industrial transformation  to establish itself as a global innovation power . A critical analysis of internal data and policies, including the findings of the

The Geopolitics of Pharmaceuticals and the Mapping of Chinese Dominance The Chinese biopharmaceutical industry is accelerating to complete a strategic industrial transformation, definitively surpassing its role as a leader in generic API production (with an estimated 80% control of the global supply chain in 2023) to establish itself as a global power in strategic innovation. As mentioned , this transition, in line with the objectives of the 14th Five-Year Plan, the Made in C